{"id":"NCT01070303","sponsor":"Abbott","briefTitle":"Remission in Subjects With Crohn's Disease, Open Label Extension","officialTitle":"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Maintenance of Clinical Remission in Subjects With Crohn's Disease, Open Label Extension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2002-08","primaryCompletion":"2008-12","completion":"2008-12","firstPosted":"2010-02-18","resultsPosted":"2010-05-07","lastUpdate":"2011-04-11"},"enrollment":177,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Crohn's Disease"],"interventions":[{"type":"BIOLOGICAL","name":"Adalimumab 40 mg eow or ew","otherNames":["Adalimumab","Humira"]}],"arms":[{"label":"Adalimumab 40 mg every other week or every week","type":"EXPERIMENTAL"}],"summary":"The objectives were: (1) To demonstrate the efficacy of adalimumab in the long-term maintenance of clinical remission in participants with Crohn's disease; and (2) To delineate the long-term safety of adalimumab when administered to participants with Crohn's disease.","primaryOutcome":{"measure":"Number of Participants Achieving Clinical Remission (Crohn's Disease Activity Index[CDAI] <150 Points) at Week 104 of Study M02-433 (Starting From Week 0 of NCT00055497) (Through 1 Year of Participation in NCT01070303).","timeFrame":"Week 104","effectByArm":[{"arm":"Remitters","deltaMin":29,"sd":null},{"arm":"Non-Remitters","deltaMin":71,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":43,"countries":["United States"]},"refs":{"pmids":["29380251"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":55},"commonTop":["Crohn's disease","Nasopharyngitis","Nausea","Headache","Abdominal pain"]}}